4.8 Review

Cellular Plasticity, Reprogramming, and Regeneration: Metaplasia in the Stomach and Beyond

Journal

GASTROENTEROLOGY
Volume 162, Issue 2, Pages 415-430

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2021.10.036

Keywords

-

Funding

  1. Department of Veterans Affairs Merit Review Award [IBX000930]
  2. National Institutes of Health (NIH) [RO1 DK101332, R01DK094989, R01DK105129, R01DK110406, P30 DK052574, P30 DK056338, R01CA239645, R01CA246208]
  3. Department of Defense [CA160479]
  4. Cancer UK Grand Challenge Award [29075]
  5. BETRNet [U54CA163060]

Ask authors/readers for more resources

The mucosa of the body of the stomach uses depth-dependent mechanisms to respond to injury, leading to various histopathological changes and potential progression to dysplasia and cancer. This metaplasia process is broadly conserved across tissues and species, involving specific cytokines in facilitating the reprogramming of cells into different types, with implications for diagnostic and clinical purposes.
The mucosa of the body of the stomach (ie, the gastric corpus) uses 2 overlapping, depth-dependent mechanisms to respond to injury. Superficial injury heals via surface cells with histopathologic changes like foveolar hyperplasia. Deeper, usually chronic, injury/inflammation, most frequently induced by the carcinogenic bacteria Helicobacter pylori, elicits glandular histopathologic alterations, initially manifesting as pyloric (also known as pseudopyloric) metaplasia. In this pyloric metaplasia, corpus glands become antrum (pylorus)-like with loss of acid-secreting parietal cells (atrophic gastritis), expansion of foveolar cells, and reprogramming of digestive enzyme-secreting chief cells into deep antral gland-like mucous cells. After acute parietal cell loss, chief cells can reprogram through an orderly stepwise progression (paligenosis) initiated by interleukin-13-secreting innate lymphoid cells (ILC2s). First, massive lysosomal activation helps mitigate reactive oxygen species and remove damaged organelles. Second, mucus and wound-healing proteins (eg, TFF2) and other transcriptional alterations are induced, at which point the reprogrammed chief cells are recognized as mucus-secreting spasmolytic polypeptide-expressing metaplasia cells. In chronic severe injury, glands with pyloric metaplasia can harbor both actively proliferating spasmolytic polypeptide-expressing metaplasia cells and eventually intestine-like cells. Gastric glands with such lineage confusion (mixed incomplete intestinal metaplasia and proliferative spasmolytic polypeptide-expressing metaplasia) may be at particular risk for progression to dysplasia and cancer. A pyloric-like pattern of metaplasia after injury also occurs in other gastrointestinal organs including esophagus, pancreas, and intestines, and the paligenosis program itself seems broadly conserved across tissues and species. Here we discuss aspects of metaplasia in stomach, incorporating data derived from animal models and work on human cells and tissues in correlation with diagnostic and clinical implications.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available